Literature DB >> 8109935

Influence of local radiotherapy on penetration of fluconazole into human saliva.

J Oliary1, M Tod, K Louchahi, O Petitjean, B Frachet, V Le Gros, N Brion.   

Abstract

The pharmacokinetics of fluconazole (50 mg, single oral dose) in saliva and plasma were determined for five healthy subjects and five patients who underwent radiotherapy (dose, > 45 Gy over a 6-week period) in the salivary gland area and suffered from oropharyngeal candidiasis. Saliva was collected after electrical stimulation. Fluconazole was measured by liquid chromatography. From healthy volunteers and patients, saliva and plasma were sampled from 0 to 24 h. Although fluconazole penetration kinetics were significantly slowed down in irradiated patients, saliva concentrations of fluconazole were higher than those in the plasma, except at 1 h. In the postdistribution phase, the saliva/plasma concentration ratio was in the range of 1.2 to 1.4, and there was no significant difference between healthy subjects and patients. The saliva concentration of fluconazole was over 1 mg/liter throughout the entire interval 2 to 24 h after drug intake. From these results, the clinical efficacy of fluconazole for oropharyngeal candidiasis is not expected to be less than that in subjects with normal salivary glands, provided that salivary secretion remains.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8109935      PMCID: PMC192775          DOI: 10.1128/AAC.37.12.2674

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  A study of the mechanism of transport of diphenylhydantoin in the rat submaxillary gland in vitro.

Authors:  M A Allen; J M Wrenn; J W Putney; J F Borzelleca
Journal:  J Pharmacol Exp Ther       Date:  1976-05       Impact factor: 4.030

Review 2.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

3.  Pharmacokinetics of tolbutamide: prediction by concentration in saliva.

Authors:  S B Matin; S H Wan; J H Karam
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

4.  Estimation of pharmacokinetic parameters of lithium from saliva and urine.

Authors:  U Groth; W Prellwitz; E Jähnchen
Journal:  Clin Pharmacol Ther       Date:  1974-09       Impact factor: 6.875

5.  The excretion of drugs in saliva. Antibiotics.

Authors:  J F Borzelleca; H M Cherrick
Journal:  J Oral Ther Pharmacol       Date:  1965-11

6.  Dialysis of ephedrine and pentobarbital from whole human saliva and simulated saliva.

Authors:  R E Davis; C W Hartman; J H Fincher
Journal:  J Pharm Sci       Date:  1971-03       Impact factor: 3.534

7.  Clearance concept in salivary drug excretion. Part I: theory.

Authors:  J Zuidema; C A van Ginneken
Journal:  Pharm Acta Helv       Date:  1983

8.  Saliva-plasma drug concentration ratios during absorption: theoretical considerations and pharmacokinetic implications.

Authors:  J Posti
Journal:  Pharm Acta Helv       Date:  1982

9.  Pharmacokinetics of 18F-labeled fluconazole in healthy human subjects by positron emission tomography.

Authors:  A J Fischman; N M Alpert; E Livni; S Ray; I Sinclair; R J Callahan; J A Correia; D Webb; H W Strauss; R H Rubin
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

10.  Saliva secretion of chloroquine in man.

Authors:  F A Ogubona; A A Lawal; C O Onyeji
Journal:  J Pharm Pharmacol       Date:  1986-07       Impact factor: 3.765

View more
  6 in total

1.  Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.

Authors:  D Debruyne
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

2.  Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules.

Authors:  C H Koks; P L Meenhorst; M J Hillebrand; A Bult; J H Beijnen
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

3.  Clinical validation of the analysis of fluconazole in oral fluid in hospitalized children.

Authors:  Kim C M van der Elst; Manouche van Alst; Marjolijn N Lub-de Hooge; Kai van Hateren; Jos G W Kosterink; Jan-Willem C Alffenaar; Elisabeth H Schölvinck
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

Review 4.  Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients.

Authors:  K L Goa; L B Barradell
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

5.  Fluconazole concentrations in saliva from AIDS patients with oropharyngeal candidosis refractory to treatment with fluconazole.

Authors:  D Garcia-Hermoso; F Dromer; L Improvisi; F Provost; B Dupont
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

6.  Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review.

Authors:  Hannah Yejin Kim; Anne-Grete Märtson; Erwin Dreesen; Isabel Spriet; Sebastian G Wicha; Andrew J McLachlan; Jan-Willem Alffenaar
Journal:  Front Pharmacol       Date:  2020-06-12       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.